171 related articles for article (PubMed ID: 29558784)
1. Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients.
Negro R; Greco EL; Greco G
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):215-219. PubMed ID: 29558784
[TBL] [Abstract][Full Text] [Related]
2. Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus.
Del Prato S; Fleck P; Wilson C; Chaudhari P
Diabetes Obes Metab; 2016 Jun; 18(6):623-7. PubMed ID: 26865535
[TBL] [Abstract][Full Text] [Related]
3. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
Del Prato S; Camisasca R; Wilson C; Fleck P
Diabetes Obes Metab; 2014 Dec; 16(12):1239-46. PubMed ID: 25132212
[TBL] [Abstract][Full Text] [Related]
4. Alogliptin: safety, efficacy, and clinical implications.
Marino AB; Cole SW
J Pharm Pract; 2015 Feb; 28(1):99-106. PubMed ID: 24532820
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Kaku K; Itayasu T; Hiroi S; Hirayama M; Seino Y
Diabetes Obes Metab; 2011 Nov; 13(11):1028-35. PubMed ID: 21682833
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
[TBL] [Abstract][Full Text] [Related]
7. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.
Pratley RE; Fleck P; Wilson C
Diabetes Obes Metab; 2014 Jul; 16(7):613-21. PubMed ID: 24400655
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
[TBL] [Abstract][Full Text] [Related]
10. Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors.
Masuda K; Aoki K; Kamiko K; Takihata M; Ito Y; Nagakura M; Kawasaki S; Akema N; Hasegawa M; Nakajima S; Shinoda K; Toumura S; Tsunoda S; Enomoto H; Shimotomai H; Terauchi Y
Expert Opin Pharmacother; 2013 Jun; 14(9):1111-8. PubMed ID: 23600363
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
Nauck MA; Ellis GC; Fleck PR; Wilson CA; Mekki Q;
Int J Clin Pract; 2009 Jan; 63(1):46-55. PubMed ID: 19125992
[TBL] [Abstract][Full Text] [Related]
12. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Rosenstock J; Wilson C; Fleck P
Diabetes Obes Metab; 2013 Oct; 15(10):906-14. PubMed ID: 23531118
[TBL] [Abstract][Full Text] [Related]
13. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Seino Y; Fujita T; Hiroi S; Hirayama M; Kaku K
Curr Med Res Opin; 2011 Nov; 27 Suppl 3():21-9. PubMed ID: 22106975
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes.
Kaku K; Sumino S; Katou M; Nishiyama Y; Kinugawa Y
Diabetes Obes Metab; 2017 Mar; 19(3):463-467. PubMed ID: 27891757
[TBL] [Abstract][Full Text] [Related]
15. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus.
Yue WS; Lau KK; Siu CW; Wang M; Yan GH; Yiu KH; Tse HF
Cardiovasc Diabetol; 2011 Dec; 10():113. PubMed ID: 22185563
[TBL] [Abstract][Full Text] [Related]
16. Effects of metformin and alogliptin on body composition in people with type 2 diabetes.
Takeshita Y; Kita Y; Kato KI; Kanamori T; Misu H; Kaneko S; Takamura T
J Diabetes Investig; 2019 May; 10(3):723-730. PubMed ID: 30156056
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Pratley RE; Kipnes MS; Fleck PR; Wilson C; Mekki Q;
Diabetes Obes Metab; 2009 Feb; 11(2):167-76. PubMed ID: 19125778
[TBL] [Abstract][Full Text] [Related]
19. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.
Rosenstock J; Rendell MS; Gross JL; Fleck PR; Wilson CA; Mekki Q
Diabetes Obes Metab; 2009 Dec; 11(12):1145-52. PubMed ID: 19758359
[TBL] [Abstract][Full Text] [Related]
20. Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients.
Chen LL; Liao YF; Zeng TS; Yu F; Li HQ; Feng Y
Endocrine; 2010 Oct; 38(2):266-75. PubMed ID: 20972736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
